Lipid-Lowering Agents - Pakistan

Pakistan

The revenue in the Lipid-Lowering Agents market in Pakistan is forecasted to reach US$7.33m in 2024.
It is expected to exhibit an annual growth rate (CAGR 2024-2028) of 0.14%, leading to a market volume of US$7.37m by 2028.
In terms of global comparison, United States is anticipated to generate the highest revenue in the market, amounting to US$4,427.00m in 2024.
The demand for Lipid-Lowering Agents in Pakistan is steadily increasing due to the rising prevalence of cardiovascular diseases in the country.

Key regions: Italy, Japan, France, Brazil, Australia

Market

Region

Region comparison

Currency

Analyst Opinion

The demand for Lipid-Lowering Agents in Pakistan has been on the rise in recent years.

Customer preferences: Pakistan has a high prevalence of cardiovascular diseases, which has led to an increase in demand for Lipid-Lowering Agents. Patients are becoming more aware of the benefits of these drugs and are seeking them out to manage their conditions. Additionally, there is a growing preference for generic drugs due to their affordability.

Trends in the market: The Lipid-Lowering Agents market in Pakistan is expected to continue growing due to the increasing incidence of cardiovascular diseases. The market is dominated by statins, which are the most commonly prescribed Lipid-Lowering Agents in the country. However, there is also a growing demand for non-statin drugs such as PCSK9 inhibitors and omega-3 fatty acids.

Local special circumstances: One of the unique factors in the Pakistani market is the prevalence of counterfeit drugs. This has led to concerns among patients about the safety and efficacy of the drugs they are taking. To address this issue, the government has implemented stricter regulations and is working to improve the quality control of drugs in the country.

Underlying macroeconomic factors: Pakistan has a large population and a growing middle class, which has led to an increase in demand for healthcare services. The government has been investing in healthcare infrastructure and has made efforts to improve access to affordable healthcare for all citizens. Additionally, the pharmaceutical industry in Pakistan is growing, which has led to increased competition and innovation in the market.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.